Medscape9d
Bivalent RSV Vaccine Shows Sustained Efficacy and Safety Through Two Seasons in Older Adults
The bivalent respiratory syncytial virus prefusion F vaccine is highly effective and well tolerated against RSV-associated ...
Pharmabiz12h
Pfizer’s RSV vaccine Abrysvo receives European approval to help protect adults aged 18-59 against RSV lower respiratory tract disease
Pfizer’s RSV vaccine Abrysvo receives European approval to help protect adults aged 18-59 against RSV lower respiratory tract disease: New York Wednesday, April 2, 2025, 09:00 H ...
BioWorld6d
Decoy Therapeutics’ antiviral candidates show broad activity against multiple viruses
Decoy Therapeutics Inc. has announced that a series of antiviral drug candidates previously designed by its Imp3act platform ...
Mirage News8d
Boosting RSV Surveillance in Mongolia
The respiratory syncytial virus (RSV) infects cells along the human respiratory tract, from the nose to the lungs. Each year ...
Winston-Salem Journal6d
Triad healthcare systems ending child visitor restrictions Thursday as flu deaths drop
The Triad's three main healthcare systems separately announced Wednesday they will lift at 7 a.m. Thursday their respiratory ...
BioPharma Dive11d
Delayed CDC meeting on vaccines is rescheduled to April
A panel of CDC advisers, who had been set to meet in February, will discuss the current measles outbreak as well as ...
PharmiWeb2d
Moderna Receives Medicines and Healthcare Products Regulatory Agency Marketing Authorization in the UK for RSV Vaccine
Moderna, Inc. (NASDAQ:MRNA) today announced that the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK has granted marketing authorization for mRESVIA (mRNA-1345), indicated for ...